How do orfoglipron and Wegovy tablets differ to the injectable formulations
This comes directly from the clinical trial design, and four weeks is generally sufficient for most people to adapt to each new dose level before moving up
Side Effects & Safety Nausea most common (~33% at high doses), dose-dependent, typically improves over time GI effects vomiting, diarrhea, constipation, slowed gastric emptying (GLP-1 class effects) Heart rate changes transient increases observed in trials, peaked at 24 weeks then declined Injection site reactions mild redness or irritation Gallbladder risk rapid weight loss increases gallstone risk (common with any rapid weight loss method) No major safety signals in 48-week trial up to 12 mg weekly At community doses (1.5 mg/week), side effects are notably milder than high-dose trial groups Dosage Chart This dosage chart consolidates the doses reported in published Phase 2 trials and self-reported community protocols, expressed in milligrams (mg) and converted to units on a standard 100-unit / 1mL insulin syringe
Novo Nordisk launches first and only multi-month subscription program for FDA-approved Wegovy, offering savings of up to $1,200/year
Interesting it got approved under the National Priority Voucher pilot, that could speed rollout
But the pill versions tend to lead to less weight loss than the weekly injections a gap that could make them less appealing to patients
